<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054452</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00203-38</org_study_id>
    <nct_id>NCT05054452</nct_id>
  </id_info>
  <brief_title>Predicting Fluid Responsiveness in Mechanically Ventilated Critically Ill Children and Neonates Using Transthoracic Echocardiography</brief_title>
  <acronym>PREDIPEN</acronym>
  <official_title>Predicting Fluid Responsiveness in Mechanically Ventilated Critically Ill Children and Neonates Using Transthoracic Echocardiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Initial fluid resuscitation remains the first treatment step for most children experiencing&#xD;
      circulatory failure and/or systemic hypotension. Only one-half of these patients respond to&#xD;
      fluid administration by a significant increase in cardiac output. A positive fluid balance is&#xD;
      a poor prognostic factor that increases mortality. There are few markers validated in&#xD;
      children to assess volume reactivity by dynamic ultrasound parameters mainly based on&#xD;
      heart-lung interaction.&#xD;
&#xD;
      In this work, we propose to investigate whether dynamic parameters validated in adults, such&#xD;
      as the superior vena caval collapsibility and the variability of cardiac output during an&#xD;
      end-expiratory and end-inspiratory occlusion, are also reliable indicators of volume&#xD;
      responsiveness in sedated children under controlled-mode ventilation.&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After standardized volume expansion, patients who present an increase of cardiac index&#xD;
      measured by transthoracic echocardiography greater than or equal to 15% of baseline&#xD;
      measurement will be considered responders .&#xD;
&#xD;
      A previous similar study using respiratory variations in aortic blood flow to predict fluid&#xD;
      responsiveness in ventilated children reported a ROC curve area 0.85 (Durand et al., 2008),&#xD;
      while the prevalence rate of circulatory failure was 50%. Given these assumptions, a sample&#xD;
      size of 38 subjects per group (Responders / No responders) was estimated to provide a AUC&#xD;
      equivalent. A total of 76 subjects should be included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac index measured by transthoracic echocardiography</measure>
    <time_frame>Through the end of the hospitalisation, a maximum of 2 months</time_frame>
    <description>After fluid administration, patients who present an increase of cardiac index measured by transthoracic echocardiography greater than or equal to 15% of baseline measurement will be considered responders .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-tidal carbon dioxide levels</measure>
    <time_frame>Through the end of the hospitalisation, a maximum of 2 months</time_frame>
    <description>ETCO2 measurements using sidestream microstream technology before and after fluid administration will be compared to cardiac index measured by transthoracic echocardiography, ETCO2 increment of 5% is expected in responders patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Fluid Therapy</condition>
  <condition>Hemodynamics</condition>
  <condition>Hypovolemia</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Echocardiographic assessment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Echocardiographic assessment</intervention_name>
    <description>At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.</description>
    <arm_group_label>Echocardiographic assessment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Patient &lt; 18 years (child and neonate)&#xD;
&#xD;
          -  Sedated and mechanically ventilated under controlled-mode ventilation&#xD;
&#xD;
          -  In whom fluid administration was planned by the attending physicians&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  High-frequency oscillatory ventilation&#xD;
&#xD;
          -  Cardiac arrhythmia&#xD;
&#xD;
          -  Congenital heart defect&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Barreault, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bicetre Hospital (AP-HP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Barreault, Doctor</last_name>
    <phone>+33145213205</phone>
    <email>simon.barreault@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bicetre Hospital</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon BARREAULT, Doctor</last_name>
      <phone>+33 1 45 21 32 05</phone>
      <email>simon.barreault@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>critically ill</keyword>
  <keyword>fluid therapy</keyword>
  <keyword>fluid responsiveness</keyword>
  <keyword>hemodynamics</keyword>
  <keyword>hypovolemia</keyword>
  <keyword>shock</keyword>
  <keyword>echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

